Ultrasound assessment of schistosomiasis.

In 2000, the World Health Organization (WHO) issued an ultrasound field protocol for assessing the morbidity due to Schistosoma (S.) haematobium and S. mansoni. The experience with this classification has recently been reviewed systematically. The WHO protocol was well accepted worldwide. Here we review the use of ultrasound to assess the morbidity due to schistosomiasis with emphasis on easy, quick, and reproducible ways that can be used in the field. Findings obtained with high-end ultrasound scanners in the hospital setting that might eventually have applications in the field are also described.

Schistosoma haematobium infections acquired in Corsica, France, August 2013.

A 12 year-old boy in Germany developed urinary schistosomiasis in January 2014. He had bathed in rivers in south-eastern Corsica five months earlier. Before this case, human schistomiasis had not been reported on the island, although its vector, the snail Bulinus truncatus, locally transmitted the zoonotic Schistosoma bovis. The boy's father excreted S. haematobium ova that were not viable; the boy's three siblings had a positive serology against schistosomes.

Plasmodium knowlesi infection imported to Germany, January 2013.

Plasmodium knowlesi was known as a plasmodium of macaques until P. knowlesi transmission to humans was recognised in Borneo and later throughout South-East Asia. We describe here a case of a P. knowlesi infection imported to Germany from Thailand. The patient had not taken antimalarial chemoprophylaxis and suffered from daily fever attacks. Microscopy revealed trophozoites and gametocytes resembling P. malariae. P. knowlesi malaria was confirmed by PCR.

[Epidemiological and clinical characteristics of patients with echinococcosis - management in an infectiological service in Germany]. / Epidemiologisch-klinische Charakteristika von Patienten mit zystischer Echinokokkose.

BACKGROUND AND OBJECTIVE: Cystic echinococcosis (CE) is a widespread zoonosis. Difficulties in patient care were investigated in order to improve the clinical management of CE patients. METHODS: 65 patients with CE attending our service between 1999 and 2011 were interviewed for their history. Previous diagnostic findings were taken into account. Diagnosis, staging and therapy relied on laboratory and imaging findings. RESULTS: 56 patients were immigrants and nine of German origin. 55 of 59 evaluable patients had been living in rural areas for many years. 34 of 35 patients recalled dog contacts. Symptoms had indicated CE in 21 of 59 (36 %) cases only, whereas CE was mostly detected accidentally. Diagnosis was hampered by false negative serological results (IHA false negative in 11 of 60 cases [18 %], EIA in 8 of 53 [15 %]), the low frequency of eosinophilia (15/61 [25 %]) and of IgE increase (27/57 [47 %]). Percutaneous treatment or surgery was performed in active CE of the liver; disseminated CE was treated non-surgically. Inactive CE cases were monitored without any intervention. Relapses occurred in 7 of 51 (14 %) patients with follow-up: one after surgery, six after conservative treatment. CONCLUSION: The diagnosis of CE is delayed by the paucity of characteristic symptoms and the inconsistency of serologic results. Assessment of cyst morphology and localisation are particularly important for diagnosis, staging and follow-up. CE requires an interdisciplinary management which should be coordinated by specialized infectious diseases centres.

Schistosoma mansoni: schistosomicidal effect of mefloquine and primaquine in vitro.

We investigated the effects of the anti-malarials mefloquine and primaquine against the juvenile and adult life stages of Schistosoma mansoniin vitro. Cercariae were incubated with 0.5 µg/ml, 1 µg/ml and 2 µg/ml mefloquine or primaquine and with 1 µg/ml praziquantel for 12h. Schistosomula, pre-adults and adults were incubated with 0.5 µg/ml, 1 µg/ml and 2 µg/ml mefloquine or primaquine and with 1 µg/ml praziquantel for 7 days. The viability status was classified as viable, damaged or dead and was checked every 3h for cercariae and every 12h for schistosomula, pre-adults and adults. Both, mefloquine and primaquine show time and dose-dependent schistosomicidal effects on the four life stages of S. mansoni. The promising in vitro effects on all stages of the blood fluke S. mansoni warrants further evaluation of both anti-malarials and their derivatives for their prophylactic and therapeutic values in early and late schistosomiasis in field trials.

Schistosomula, pre-adults and adults of Schistosoma mansoni ingest fluorescence-labelled albumin in vitro and in vivo: implication for a drug-targeting model.

SUMMARY OBJECTIVE: Bilharziosis is one of the most important helminthal infections in humans and is caused by blood flukes of the genus Schistosoma. Three different life stages of the parasite occur within the mammalian host: schistosomula located in the skin, pre-adults located in the lung and adult worms located in the portal venous system. Erythrocytes are a major source of nutrient supply for adults. However, sources of nutrition for the developing stages are still unclear. METHODS: To investigate whether schistosomula, pre-adults and adults of Schistosoma mansoni ingest human serum albumin (HSA) in vitro, these life stages were incubated with aminofluorescein-labelled human serum albumin (Afl-HSA) for 5 h. To test the uptake of albumin in vivo, the albumin conjugate was given intravenously to S. mansoni infected NMRI mice 24 h before harvesting the 3 life stages. RESULTS: In comparison to the control group schistosomula, pre-adults, and adults showed an accumulation of Afl-HSA within the oesophagus and intestinal caecum in vitro and in vivo. CONCLUSION: Our findings suggest that albumin seems to be a major source of energy supply for the early schistosomal life stages and an additive energy support for adult worms. Since albumin has been used successfully as a drug carrier for chemotherapeutic substances against malignant disorders, further studies will focus on albumin as a carrier for anthelminthics in a drug-targeting model.